MGI

MGI is a world-leading life science innovator that has been committed to developing and promoting advanced life science tools for future healthcare since its inception in 2016. Based in China, MGI specializes in R&D, production, and sales of DNA sequencing instruments, reagents, and related products for applications in life science research, agriculture, precision medicine, and healthcare. With a focus on the production of clinical high-throughput gene sequencers, MGI has established itself as a leading producer in the industry. In addition, its multi-omics platforms encompass genetic sequencing, medical imaging, and laboratory automation, positioning MGI at the forefront of life science innovation. Notably, MGI recently received a significant $1.00B Series B investment on 28 May 2020 from a group of prominent investors including Green Pine Capital Partners, IDG Capital, CITIC Securities, CPE Capital, and Huatai Zijin Investment. This substantial investment serves as a testament to the potential and promise attributed to MGI's innovative technologies and contributions to the life sciences industry. With this substantial backing, MGI is poised to further its advancements and make a significant impact within the biotechnology and healthcare sectors.